Blog
RSS FeedPosted by Michael Wonder on 25 Feb 2020
ICER issues final report and policy recommendations on acute treatments for migraine
25 February 2020 - Evidence on new agents lasmiditan, ubrogepant, and rimegepant judged inadequate to demonstrate superiority over more affordable triptans. ...
Posted by Michael Wonder on 24 Jan 2020
ICER releases draft evidence report on therapies for sickle cell disease
23 January 2020 - ICER’s ongoing assessment emphasises that policy makers will need to consider, in addition to traditional measures ...
Posted by Michael Wonder on 09 Dec 2019
ICER issues final report and policy recommendations for add-on therapies to treat type 2 diabetes
9 December 2019 - Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin. ...
Posted by Michael Wonder on 07 Nov 2019
ICER releases draft evidence report on acute migraine therapies
7 November 2019 - Public comment period on preliminary draft now open until 6 December 2019; requests to make oral comment ...
Posted by Michael Wonder on 01 Nov 2019
ICER report finds oral GLP-1 semaglutide, at estimated net price, less cost-effective than SGLT-2 competitor empagliflozin as add-on therapy for type 2 diabetes
1 November 2019 - Semaglutide as add-on therapy to metformin achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than ...
Posted by Michael Wonder on 17 Oct 2019
ICER issues final report and policy recommendations regarding additive treatments for cardiovascular disease
17 October 2019 - Independent appraisal committee votes that rivaroxaban and icosapent ethyl improve patient health at prices that achieve ...
Posted by Michael Wonder on 15 Aug 2019
ICER issues final report and policy recommendations regarding treatments for Duchenne muscular dystrophy
15 August 2019 - Public meeting reveals tensions inherent around high-priced treatments that lack adequate evidence of efficacy. ...
Posted by Michael Wonder on 12 Jul 2019
Aimmune statement on ICER final report on AR101 for peanut allergy
11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...
Posted by Michael Wonder on 11 Jul 2019
ICER publishes evidence report on treatments for Duchenne muscular dystrophy
11 July 2019 - No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive ...
Posted by Michael Wonder on 10 Jul 2019
ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks
10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...
Posted by Michael Wonder on 21 Jun 2019
U.S. group says Novartis MS drug price out of line with benefit
21 June 2019 - A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new ...
Posted by Michael Wonder on 20 Jun 2019
ICER issues final report and policy recommendations on esketamine for treatment-resistant depression
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical benefits of esketamine versus placebo, ...
Posted by Michael Wonder on 20 Jun 2019
Institute for Clinical and Economic Review issues final report and policy recommendations on siponimod for secondary progressive multiple sclerosis
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate siponimod offers superior effectiveness for patients ...
Posted by Michael Wonder on 13 Jun 2019
Aimmune wins over ICER for peanut allergy product
12 June 2019 - Analysts predict blockbuster status for first-in-class. ...
Posted by Michael Wonder on 28 May 2019
ICER’s assessment highlights the risk-benefit tradeoffs of investigational treatments for peanut allergy
28 May 2019 - To achieve commonly cited thresholds for cost-effectiveness, the annual price would need to be between $4,800-$7,200 for ...